Pregnancy outcome after periconceptional and first-trimester exposure to methoxsalen photochemotherapy

British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015

“…Oral psoralen is associated with reduced birth rate and teratogenicity in animal studies, [366][367][368] but this is not found in humans. [369][370][371] One study observed a marked increase in infants with low birth weights when pregnancy occurred after treatment. 370 It was thought that this may be an effect of the underlying disease rather than the treatment itself.…”

Guidelines of care for the management of psoriasis and psoriatic arthritis

“…[128][129][130] Although the rate of congenital malformations among 504 infants who were conceived and born after their mothers had received methoxsalen photochemotherapy was not higher than that found in the general population, there was an increased number of low-birthweight infants who were born to these women. 128 Oral psoralen carries a pregnancy category C rating.…”

Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases

“…No congenital anomalies were observed among 59 infants in 3 series of women who received methoxsalen photochemotherapy at the time of conception or during pregnancy. [153][154][155] Furthermore, the rate of congenital malformations was not higher than that found in the general population among 504 infants who were conceived and born after their mothers had received methoxsalen photochemotherapy. 153 However, the authors did find an increased number of low birth-weight infants who were born to this group of women.…”